215 related articles for article (PubMed ID: 24858398)
21. Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.
Alameh M; Dejesus D; Jean M; Darras V; Thibault M; Lavertu M; Buschmann MD; Merzouki A
Int J Nanomedicine; 2012; 7():1399-414. PubMed ID: 22457597
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and characterization of Fe
Arami S; Rashidi MR; Mahdavi M; Fathi M; Entezami AA
Hum Exp Toxicol; 2017 Mar; 36(3):227-237. PubMed ID: 27162247
[TBL] [Abstract][Full Text] [Related]
23. Lipoplexes versus nanoparticles: pDNA/siRNA delivery.
Khurana B; Goyal AK; Budhiraja A; Aora D; Vyas SP
Drug Deliv; 2013 Feb; 20(2):57-64. PubMed ID: 23537464
[TBL] [Abstract][Full Text] [Related]
24. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing.
Liu X; Howard KA; Dong M; Andersen MØ; Rahbek UL; Johnsen MG; Hansen OC; Besenbacher F; Kjems J
Biomaterials; 2007 Feb; 28(6):1280-8. PubMed ID: 17126901
[TBL] [Abstract][Full Text] [Related]
25. Hyaluronic acid-modified redox-sensitive hybrid nanocomplex loading with siRNA for non-small-cell lung carcinoma therapy.
Chen D; Zhang P; Li M; Li C; Lu X; Sun Y; Sun K
Drug Deliv; 2022 Dec; 29(1):574-587. PubMed ID: 35156491
[TBL] [Abstract][Full Text] [Related]
26. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery.
Yuan X; Shah BA; Kotadia NK; Li J; Gu H; Wu Z
Pharm Res; 2010 Jul; 27(7):1285-95. PubMed ID: 20309616
[TBL] [Abstract][Full Text] [Related]
27. Comparison of nanocomplexes with branched and linear peptides for siRNA delivery.
Tagalakis AD; Saraiva L; McCarthy D; Gustafsson KT; Hart SL
Biomacromolecules; 2013 Mar; 14(3):761-70. PubMed ID: 23339543
[TBL] [Abstract][Full Text] [Related]
28. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
29. GABA
Ni S; Liu Y; Tang Y; Chen J; Li S; Pu J; Han L
Carbohydr Polym; 2018 Jan; 179():135-144. PubMed ID: 29111036
[TBL] [Abstract][Full Text] [Related]
30. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies.
Fernandes JC; Qiu X; Winnik FM; Benderdour M; Zhang X; Dai K; Shi Q
Int J Nanomedicine; 2012; 7():5833-45. PubMed ID: 23209368
[TBL] [Abstract][Full Text] [Related]
31. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
32. Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.
Salimifard S; Karoon Kiani F; Sadat Eshaghi F; Izadi S; Shahdadnejad K; Masjedi A; Heydari M; Ahmadi A; Hojjat-Farsangi M; Hassannia H; Mohammadi H; Boroumand-Noughabi S; Keramati MR; Jadidi-Niaragh F
Life Sci; 2020 Nov; 260():118423. PubMed ID: 32941896
[TBL] [Abstract][Full Text] [Related]
33. Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma.
Labala S; Jose A; Venuganti VV
Colloids Surf B Biointerfaces; 2016 Oct; 146():188-97. PubMed ID: 27318964
[TBL] [Abstract][Full Text] [Related]
34. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Jose A; Labala S; Ninave KM; Gade SK; Venuganti VVK
AAPS PharmSciTech; 2018 Jan; 19(1):166-175. PubMed ID: 28639178
[TBL] [Abstract][Full Text] [Related]
35. Chitosan hydrogel for localized gene silencing.
Han HD; Mora EM; Roh JW; Nishimura M; Lee SJ; Stone RL; Bar-Eli M; Lopez-Berestein G; Sood AK
Cancer Biol Ther; 2011 May; 11(9):839-45. PubMed ID: 21358280
[TBL] [Abstract][Full Text] [Related]
36. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects.
Tahara K; Yamamoto H; Hirashima N; Kawashima Y
Eur J Pharm Biopharm; 2010 Mar; 74(3):421-6. PubMed ID: 20034563
[TBL] [Abstract][Full Text] [Related]
37. Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique.
Okuda T; Kito D; Oiwa A; Fukushima M; Hira D; Okamoto H
Biol Pharm Bull; 2013; 36(7):1183-91. PubMed ID: 23811567
[TBL] [Abstract][Full Text] [Related]
38. Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells.
Hibbitts A; O'Mahony AM; Forde E; Nolan L; Ogier J; Desgranges S; Darcy R; MacLoughlin R; O'Driscoll CM; Cryan SA
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):466-77. PubMed ID: 24665866
[TBL] [Abstract][Full Text] [Related]
39. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression.
Wei W; Lv PP; Chen XM; Yue ZG; Fu Q; Liu SY; Yue H; Ma GH
Biomaterials; 2013 May; 34(15):3912-23. PubMed ID: 23453062
[TBL] [Abstract][Full Text] [Related]
40. Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA.
Capel V; Vllasaliu D; Watts P; Clarke PA; Luxton D; Grabowska AM; Mantovani G; Stolnik S
Drug Deliv; 2018 Nov; 25(1):644-653. PubMed ID: 29493294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
